We have long understood the connection between diabetes and a host of serious health risks. The importance of managing blood sugar to prevent or control diabetes is a cornerstone of modern public health advice. But what if your cancer risk is influenced by your blood sugar levels, even if you don't have diabetes?

A large-scale prospective study in Japan, following 29,629 individuals, has uncovered some surprising and crucial connections between hemoglobin A1c (HbA1c)—a key marker for long-term blood sugar control—and the risk of developing cancer. The findings challenge the clear line we often draw between "diabetic" and "healthy," revealing that the risks exist on a clear spectrum. Here are the three key takeaways.

1. "High-Normal" Blood Sugar Is a Hidden Risk Factor

The study's most significant finding is that a higher cancer risk isn't exclusive to those with diabetes. The data reveals a clear dose-response relationship: as blood sugar rises, so does cancer risk.

Individuals with HbA1c levels in the high-normal, or "pre-diabetic," range of 6.0% to 6.4% showed a substantial 28% higher risk of developing any type of cancer compared to people with optimal levels (5.0% to 5.4%). As levels climbed into the diabetic range (≥6.5%), that risk jumped even higher, to a significant 43% increase. This is an impactful discovery because it extends the danger zone well beyond a formal diabetes diagnosis, challenging the perception that only diabetic-level glucose is a cause for concern.

2. The Paradox of Low Blood Sugar and Liver Cancer

Counter-intuitively, the study also found that individuals with the lowest HbA1c levels (below 5.0%) had a 27% higher risk for cancer overall. However, researchers uncovered a critical twist that explains this apparent paradox.

This increased risk was driven almost entirely by a dramatic association with a single type of cancer: liver cancer. This group had a more than three-fold increased risk of developing liver cancer. Researchers hypothesized that in this context, a low HbA1c reading may not be the cause of the cancer, but rather a potential symptom of pre-existing liver problems. Impaired liver function can artificially lower HbA1c levels, meaning the reading could be a marker of underlying disease. When the researchers excluded liver cancer cases from their analysis, the elevated risk for the low HbA1c group vanished, and the link between rising blood sugar and overall cancer risk became a clear, linear trend.

3. The Link Varies by Cancer Type

The relationship between blood sugar and cancer isn't uniform across all types of malignancies. The study found particularly strong connections for specific cancers, revealing an escalating risk as HbA1c levels increased.

The link was especially pronounced for colorectal cancer. Individuals with HbA1c levels in the pre-diabetic 6.0-6.4% range had a 51% higher risk, and this surged to a 70% higher risk for those with levels of 6.5% or greater. The researchers noted this association was specific to colon cancer, not rectal cancer.

The risk was particularly stark for women and breast cancer. Women with HbA1c levels in the diabetic range (≥6.5%) faced a staggering 183% higher risk of developing breast cancer, a dramatic finding that underscores the potency of this connection.

This study reinforces that managing blood sugar is a crucial health goal for reasons that go far beyond diabetes prevention. The findings suggest that glycemic control could be an important component of a comprehensive cancer prevention strategy, even for those who don't have diabetes.

As the study's authors conclude:

"Our findings corroborate the notion that glycemic control in individuals with high HbA1c levels may be important not only to prevent diabetes but also to prevent cancer."

If even "high-normal" blood sugar can increase health risks, what does this mean for our personal health goals and the future of preventative medicine?

‍